Pro-Dex, Inc. (NASDAQ:PDEX)‘s stock had its “buy” rating reissued by equities researchers at Ascendiant Capital Markets in a research report issued to clients and investors on Friday. They currently have a $9.00 price target on the medical instruments supplier’s stock, up from their prior price target of $8.00. Ascendiant Capital Markets’ target price would suggest a potential upside of 20.00% from the stock’s current price.

Pro-Dex (NASDAQ PDEX) traded up 2.74% during mid-day trading on Friday, reaching $7.50. The company had a trading volume of 43,362 shares. The stock has a 50 day moving average price of $6.46 and a 200-day moving average price of $5.56. The stock has a market capitalization of $30.11 million, a P/E ratio of 6.77 and a beta of -0.42. Pro-Dex has a 12-month low of $3.80 and a 12-month high of $7.55.

TRADEMARK VIOLATION NOTICE: “Pro-Dex’s (PDEX) “Buy” Rating Reiterated at Ascendiant Capital Markets” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at

Pro-Dex Company Profile

Pro-Dex, Inc (Pro-Dex) designs and produces surgical and dental instruments and motion control products used in the medical, factory automation and scientific research industries. The Company operates through four segments: Pro-Dex, OMS, Fineline and Engineering Services Division (ESD). The Pro-Dex segment provides primarily medical and dental instruments using shared production and assembly machines and workforce.

Receive News & Ratings for Pro-Dex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex Inc. and related companies with's FREE daily email newsletter.